Intensive care unit-acquired weakness clinical phenotypes and molecular mechanisms

American Journal of Respiratory and Critical Care Medicine

Volumn 187, Issue 3, 2013, Pages 238-246

  Batt, Jane ^a   Dos Santos, Claudia C ^a,b   Cameron, Jill I ^c   Herridge, Margaret S ^d  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b Institute of Medical Science   (Canada)

^c Department of Occupational Science and Occupational Therapy ^*  (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Caregiver functional outcomes; Critical illness functional outcomes; Critical illness myopathy; Critical illness polyneuropathy

Indexed keywords

ATROGIN 1; CYTOCHROME C OXIDASE; FREE RADICAL; MUSCLE RING FINGER 1 PROTEIN; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEASOME; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); RYANODINE RECEPTOR 1; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; TRANSCRIPTION FACTOR FOXO; UBIQUITIN;

ADL DISABILITY; ARTICLE; ARTIFICIAL VENTILATION; BLOOD NERVE BARRIER; CAREGIVER BURDEN; CHRONIC OBSTRUCTIVE LUNG DISEASE; COGNITION; COGNITIVE DEFECT; CONCEPTUAL FRAMEWORK; CONGESTIVE HEART FAILURE; CRITICAL ILLNESS; CRITICAL ILLNESS MYOPATHY; CRITICAL ILLNESS POLYNEUROPATHY; CRITICALLY ILL PATIENT; DISABILITY; DISEASE ASSOCIATION; ENDONEURIUM; EXCITATION CONTRACTION COUPLING; GROUPS BY AGE; HOSPITAL INFECTION; HUMAN; IMMUNE DEFICIENCY; INTENSIVE CARE UNIT ACQUIRED WEAKNESS; LENGTH OF STAY; LIFESTYLE; MITOCHONDRIAL MYOPATHY; MITOCHONDRIAL RESPIRATION; MOLECULAR DYNAMICS; MOOD; MORBIDITY; MUSCLE ATROPHY; MUSCLE CHANNELOPATHY; MUSCLE CONTRACTILITY; MUSCLE DENERVATION; MUSCLE DISEASE; MUSCLE FATIGUE; MUSCLE INJURY; MUSCLE MITOCHONDRION; MUSCLE WEAKNESS; NERVE CELL MEMBRANE STEADY POTENTIAL; NERVE INJURY; NEUROPATHY; NEW YORK HEART ASSOCIATION CLASS; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; QUALITY OF LIFE; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; SEPTIC SHOCK; SEPTICEMIA; SODIUM CHANNELOPATHY; WEAKNESS; WORK RESUMPTION;

ADULT; AGE FACTORS; AGED; CAREGIVERS; COST OF ILLNESS; CRITICAL ILLNESS; DISABLED PERSONS; HUMANS; INTENSIVE CARE; INTENSIVE CARE UNITS; LENGTH OF STAY; MIDDLE AGED; MOLECULAR BIOLOGY; MUSCLE WEAKNESS; MUSCULAR ATROPHY; PHENOTYPE; POLYNEUROPATHIES; RESPIRATION, ARTIFICIAL; YOUNG ADULT;

EID: 84873346682     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201205-0954SO     Document Type: Article

References (129)

1. Levine S, Nguyen T, Taylor N, Friscia ME, Budak MT, Rothenberg P, Zhu J, Sachdeva R, Sonnad S, Kaiser LR, et al. Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans. N Engl J Med 2008;358:1327-1335.
2. Herridge MS, Tansey CM, Matte A, Tomlinson G, Diaz-Granados N, Cooper A, Guest CB, Mazer CD, Mehta S, Stewart TE, et al. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med 2011;364:1293-1304.
3. Herridge MS, Cheung AM, Tansey CM, Matte-Martyn A, Diaz-Granados N, Al Saidi F, Cooper AB, Guest CB, Mazer CD, Mehta S, et al. One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med 2003;348:683-693.
4. Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA 2010;304:1787-1794.
5. McHugh LG, Milberg JA, Whitcomb ME, Schoene RB, Maunder RJ, Hudson LD. Recovery of function in survivors of the acute respiratory distress syndrome. Am J Respir Crit Care Med 1994;150: 90-94.
6. Unroe M, Kahn JM, Carson SS, Govert JA, Martinu T, Sathy SJ, Clay AS, Chia J, Gray A, Tulsky JA, et al. One-year trajectories of care and resource utilization for recipients of prolonged mechanical ventilation: a cohort study. Ann Intern Med 2010;153:167-175.
7. de Letter MA, Schmitz PI, Visser LH, Verheul FA, Schellens RL, Op de Coul DA, van der Meche FG. Risk factors for the development of polyneuropathy and myopathy in critically ill patients. Crit Care Med 2001;29:2281-2286.
8. Hough CL. Neuromuscular sequelae in survivors of acute lung injury. Clin Chest Med 2006;27:691-703.
9. Latronico N, Bolton CF. Critical illness polyneuropathy and myopathy: a major cause of muscle weakness and paralysis. Lancet Neurol 2005; 10:931-941.
10. Barnato AE, Albert SM, Angus DC, Lave JR, Degenholtz HB. Disability among elderly survivors of mechanical ventilation. Am J Respir Crit Care Med 2011;183:1037-1042.
11. Hopkins RO, Weaver LK, Pope D, Orme JF, Bigler ED, Larson-Lohr V. Neuropsychological sequelae and impaired health status in survivors of severe acute respiratory distress syndrome. Am J Respir Crit Care Med 1999;160:50-56.
12. Hopkins RO, Weaver LK, Collingridge D, Parkinson RB, Chan KJ, Orme JF Jr. Two-year cognitive, emotional, and quality-of-life outcomes in acute respiratory distress syndrome. Am J Respir Crit Care Med 2005;171:340-347.
13. Peek GJ, Mugford M, Tiruvoipati R, Wilson A, Allen E, Thalanany MM, Hibbert CL, Truesdale A, Clemens F, Cooper N, et al. Efficacy and economic assessment of Conventional Ventilatory Support Versus Extracorporeal Membrane Oxygenation for Severe Adult Respiratory Failure (CESAR): a multicentre randomised controlled trial. Lancet 2009;374:1351-1363.
14. Chelluri L, Im KA, Belle SH, Schulz R, Rotondi AJ, Donahoe MP, Sirio CA, Mendelsohn AB, Pinsky MR. Long-term mortality and quality of life after prolonged mechanical ventilation. Crit Care Med 2004;32:61-69.
15. Combes A, Costa MA, Trouillet JL, Baudot J, Mokhtari M, Gibert C, Chastre J.Morbidity, mortality, and quality-of-life outcomes of patients requiring >14 days of mechanical ventilation. Crit Care Med 2003;31: 1373-1381.
16. Somme D, Maillet JM, Gisselbrecht M, Novara A, Ract C, Fagon JY. Critically ill old and the oldest-old patients in intensive care: shortand long-term outcomes. Intensive Care Med 2003;29:2137-2143.
17. Chelluri L, Pinsky MR, Donahoe MP, Grenvik A. Long-term outcome of critically ill elderly patients requiring intensive care. JAMA 1993; 269:3119-3123.
18. Khouli H, Astua A, Dombrowski W, Ahmad F, Homel P, Shapiro J, Singh J, Nallamothu R, Mahbub H, Eden E, et al. Changes in healthrelated quality of life and factors predicting long-term outcomes in older adults admitted to intensive care units. Crit Care Med 2011;39: 731-737.
19. Desai S, Law T, Bienvenu J, Needham D. Psychiatric long-term complications of intensive care unit survivors. Crit Care Med 2011;39:2790.
20. Cameron JI, Herridge MS, Tansey CM, McAndrews MP, Cheung AM. Well-being in informal caregivers of survivors of acute respiratory distress syndrome. Crit Care Med 2006;34:81-86.
21. Douglas SL, Daly BJ, Kelley CG, O'Toole E, Montenegro H. Impact of a disease management program upon caregivers of chronically critically ill patients. Chest 2005;128:3925-3936.
22. Bolton CF, Laverty DA, Brown JD, Witt NJ, Hahn AF, Sibbald WJ. Critically ill polyneuropathy: electrophysiological studies and differentiation from Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 1986;49:563-573.
23. Latronico N, Fenzi F, Recupero D, Guarneri B, Tomelleri G, Tonin P, De MG, Antonini L, Rizzuto N, Candiani A. Critical illness myopathy and neuropathy. Lancet 1996;347:1579-1582.
24. Sander HW, Golden M, Danon MJ. Quadriplegic areflexic ICU illness: selective thick filament loss and normal nerve histology. Muscle Nerve 2002;26:499-505.
25. Angel MJ, Bril V, Shannon P, Herridge MS. Neuromuscular function in survivors of the acute respiratory distress syndrome. Can J Neurol Sci 2007;34:427-432.
26. Latronico N, Bertolini G, Guarneri B, Botteri M, Peli E, Andreoletti S, Bera P, Luciani D, Nardella A, Vitorielli E, et al. Simplified electrophysiological evaluation of peripheral nerves in critically ill patients: the Italian multi-centre CRIMYNE Study. Crit Care 2007;11:R11.
27. Novak KR, Nardelli P, Cope TC, Filatov G, Glass JD, Khan J, Rich MM. Inactivation of sodium channels underlies reversible neuropathy during critical illness in rats. J Clin Invest 2009;119:1150-1158.
28. Gorson KC. Approach to neuromuscular disorders in the intensive care unit. Neurocrit Care 2005;3:195-212.
29. Hermans G, Vanhorebeek I, Derde S, Van den Berghe G. Metabolic aspects of critical illness polyneuromyopathy. Crit Care Med 2009;37: S391-S397.
30. Ifergane G, Bersudsky M, Kachko L, Wirguin I. Induction of conduction block by Campylobacter jejuni lipopolysaccharides and focal neural insult. J Neurol Sci 2003;213:11-14.
31. Bolton CF. Neuromuscular manifestations of critical illness. Muscle Nerve 2005;32:140-163.
32. Dori A, Ifergane G, Saar-Levy T, Bersudsky M, Mor I, Soreq H, Wirguin I. Readthrough acetylcholinesterase in inflammation-associated neuropathies. Life Sci 2007;80:2369-2374.
33. Witt NJ, Zochodne DW, Bolton CF, Grand'Maison F, Wells G, Young GB, Sibbald WJ. Peripheral nerve function in sepsis and multiple organ failure. Chest 1991;99:176-184.
34. Zochodne DW, Bolton CF, Wells GA, Gilbert JJ, Hahn AF, Brown JD, Sibbald WA. Critical illness polyneuropathy: a complication of sepsis and multiple organ failure. Brain 1987;110:819-841.
35. Op de Coul AA, Verheul GA, Leyten AC, Schellens RL, Teepen JL. Critical illness polyneuromyopathy after artificial respiration. Clin Neurol Neurosurg 1991;93:27-33.
36. Fenzi F, Latronico N, Refatti N, Rizzuto N. Enhanced expression of E-selectin on the vascular endothelium of peripheral nerve in critically ill patients with neuromuscular disorders. Acta Neuropathol 2003;106:75-82.
37. Druschky A, Herkert M, Radespiel-Troger M, Druschky K, Hund E, Becker CM, Hilz MJ, Erbguth F, Neundorfer B. Critical illness polyneuropathy: clinical findings and cell culture assay of neurotoxicity assessed by a prospective study. Intensive Care Med 2001;27: 686-693.
38. Hund E. Critical illness polyneuropathy. Curr Opin Neurol 2001;14: 649-653.
39. Verheul GA, de Jongh-Leuvenink J, Op de Coul AA, van Landeghem AA, van Puyenbroek MJ. Tumor necrosis factor and interleukin-6 in critical illness polyneuromyopathy. Clin Neurol Neurosurg 1994;96: 300-304.
40. Shimizu F, Sano Y, Haruki H, Kanda T. Advanced glycation endproducts induce basement membrane hypertrophy in endoneurial microvessels and disrupt the blood-nerve barrier by stimulating the release of TGF-b and vascular endothelial growth factor (VEGF) by pericytes. Diabetologia 2011;54:1517-1526.
41. Creagh-Brown BC, Quinlan GJ, Evans TW, Burke-Gaffney A. The RAGE axis in systemic inflammation, acute lung injury and myocardial dysfunction: an important therapeutic target? Intensive Care Med 2010;36:1644-1656.
42. Jabaudon M, Futier E, Roszyk L, Chalus E, Guerin R, Petit A, Mrozek S, Perbet S, Cayot-Constantin S, Chartier C, et al. Soluble form of the receptor for advanced glycation end products is a marker of acute lung injury but not of severe sepsis in critically ill patients. Crit Care Med 2011;39:480-488.
43. Shah KK, Yang L, Abbruscato TJ. In vitro models of the blood-brain barrier. Methods Mol Biol 2012;814:431-449.
44. Hatherell K, Couraud PO, Romero IA, Weksler B, Pilkington GJ. Development of a three-dimensional, all-human in vitro model of the blood-brain barrier using mono-, co-, and tri-cultivation Transwell models. J Neurosci Methods 2011;199:223-229.
45. Wessig C. Detection of blood-nerve barrier permeability by magnetic resonance imaging. Methods Mol Biol 2011;686:267-271.
46. Kiernan MC, Bostock H. Effects of membrane polarization and ischaemia on the excitability properties of human motor axons. Brain 2000;123:2542-2551.
47. Z'Graggen WJ, Lin CS, Howard RS, Beale RJ, Bostock H. Nerve excitability changes in critical illness polyneuropathy. Brain 2006;129: 2461-2470.
48. Kiernan MC, Walters RJ, Andersen KV, Taube D, Murray NM, Bostock H. Nerve excitability changes in chronic renal failure indicate membrane depolarization due to hyperkalaemia. Brain 2002; 125:1366-1378.
49. Krishnan AV, Phoon RK, Pussell BA, Charlesworth JA, Bostock H, Kiernan MC. Altered motor nerve excitability in end-stage kidney disease. Brain 2005;128:2164-2174.
50. Cannon SC, Bean BP. Sodium channels gone wild: resurgent current from neuronal and muscle channelopathies. J Clin Invest 2010;120:80-83.
51. Tamura N, Kuwabara S, Misawa S, Kanai K, Nakata M, Sawai S, Hattori T. Increased nodal persistent Na currents in human neuropathy and motor neuron disease estimated by latent addition. Clin Neurophysiol 2006;117:2451-2458.
52. Waldhausen E, Mingers B, Lippers P, Keser G. Critical illness polyneuropathy due to parenteral nutrition. Intensive Care Med 1997;23: 922-923.
53. Marino PL, Millili JJ. Possible role of dietary lipids in critical illness polyneuropathy. Intensive Care Med 1998;24:87.
54. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in critically ill patients.NEngl J Med 2001;345:1359-1367.
55. Braun TP, Zhu X, SzumowskiM, Scott GD, Grossberg AJ, Levasseur PR, Graham K, Khan S, Damaraju S, Colmers WF, et al. Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic-pituitary-adrenal axis. J Exp Med 2011;208:2449-2463.
56. Hirano M, Ott BR, Raps EC, Minetti C, Lennihan L, Libbey NP, Bonilla E, Hays AP. Acute quadriplegic myopathy: a complication of treatment with steroids, nondepolarizing blocking agents, or both. Neurology 1992;42:2082-2087.
57. Lecker SH, Goldberg AL, Mitch WE. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol 2006;17:1807-1819.
58. Sandri M. Signaling in muscle atrophy and hypertrophy. Physiology (Bethesda) 2008;23:160-170.
59. Attaix D, Ventadour S, Codran A, Bechet D, Taillandier D, Combaret L. The ubiquitin-proteasome system and skeletal muscle wasting. Essays Biochem 2005;41:173-186.
60. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, Goldberg AL. FoxO transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004;117:399-412.
61. Zhao J, Brault JJ, Schild A, Cao P, Sandri M, Schiaffino S, Lecker SH, Goldberg AL. FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab 2007;6:472-483.
62. Southgate RJ, Neill B, Prelovsek O, El-Osta A, Kamei Y, Miura S, Ezaki O, McLoughlin TJ, Zhang W, Unterman TG, et al. FOXO1 regulates the expression of 4E-BP1 and inhibits mTOR signaling in mammalian skeletal muscle. J Biol Chem 2007;282:21176-21186.
63. Greer EL, Oskoui PR, Banko MR, Maniar JM, Gygi MP, Gygi SP, Brunet A. The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor. J Biol Chem 2007;282:30107-30119.
64. Nakashima K, Yakabe Y. AMPK activation stimulates myofibrillar protein degradation and expression of atrophy-related ubiquitin ligases by increasing FOXO transcription factors in C2C12 myotubes. Biosci Biotechnol Biochem 2007;71:1650-1656.
65. Kandarian SC, Jackman RW. Intracellular signaling during skeletal muscle atrophy. Muscle Nerve 2006;33:155-165.
66. Batt J, Bain J, Goncalves J, Michalski B, Plant P, Fahnestock M, Woodgett J. Differential gene expression profiling of short and long term denervated muscle. FASEB J 2006;20:115-117.
67. Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, Bailey J, Price SR, Mitch WE, Goldberg AL. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 2004;18:39-51.
68. Stevenson EJ, Giresi PG, Koncarevic A, Kandarian SC. Global analysis of gene expression patterns during disuse atrophy in rat skeletal muscle. J Physiol 2003;551:33-48.
69. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001;294:1704-1708.
70. Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA 2001;98:14440-14445.
71. Llano-Diez M, Gustafson AM, Olsson C, Goransson H, Larsson L. Muscle wasting and the temporal gene expression pattern in a novel rat intensive care unit model. BMC Genomics 2011;12:602.
72. Larsson L. Experimental animal models of muscle wasting in intensive care unit patients. Crit Care Med 2007;35:S484-S487.
73. Klionsky DJ. Autophagy: from phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol 2007;8:931-937.
74. Mammucari C, Milan G, Romanello V, Masiero E, Rudolf R, Del PP, Burden SJ, Di LR, Sandri C, Zhao J, et al. FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab 2007;6:458-471.
75. Zhao J, Brault JJ, Schild A, Goldberg AL. Coordinate activation of autophagy and the proteasome pathway by FoxO transcription factor. Autophagy 2008;4:378-380.
76. O'Leary MF, Hood DA. Denervation-induced oxidative stress and autophagy signaling in muscle. Autophagy 2009;5:230-231.
77. Masiero E, Agatea L, Mammucari C, Blaauw B, Loro E, Komatsu M, Metzger D, Reggiani C, Schiaffino S, Sandri M. Autophagy is required to maintain muscle mass. Cell Metab 2009;10:507-515.
78. Tiao G, Hobler S, Wang JJ, Meyer TA, Luchette FA, Fischer JE, Hasselgren PO. Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle. J Clin Invest 1997;99:163-168.
79. Constantin D, McCullough J, Mahajan RP, Greenhaff PL. Novel events in the molecular regulation of muscle mass in critically ill patients. J Physiol 2011;589:3883-3895.
80. KlaudeM, Fredriksson K, Tjader I,Hammarqvist F,Ahlman B, Rooyackers O, Wernerman J. Proteasome proteolytic activity in skeletal muscle is increased in patients with sepsis. Clin Sci (Lond) 2007;112:499-506.
81. Roth GA, Moser B, Krenn C, Roth-Walter F, Hetz H, Richter S, Brunner M, Jensen-Jarolim E, Wolner E, Hoetzenecker K, et al. Heightened levels of circulating 20S proteasome in critically ill patients. Eur J Clin Invest 2005;35:399-403.
82. Jespersen JG, Nedergaard A, Reitelseder S, Mikkelsen UR, Dideriksen KJ, Agergaard J, Kreiner F, Pott FC, Schjerling P, Kjaer M. Activated protein synthesis and suppressed protein breakdown signaling in skeletal muscle of critically ill patients. PLoS One 2011;6:e18090.
83. de Boer MD, Selby A, Atherton P, Smith K, Seynnes OR, Maganaris CN, Maffulli N, Movin T, Narici MV, Rennie MJ. The temporal responses of protein synthesis, gene expression and cell signalling in human quadriceps muscle and patellar tendon to disuse. J Physiol 2007;585:241-251.
84. Hussain SN, Mofarrahi M, Sigala I, Kim HC, Vassilakopoulos T, Maltais F, Bellenis I, Chaturvedi R, Gottfried SB, Metrakos P, et al. Mechanical ventilation-induced diaphragm disuse in humans triggers autophagy. Am J Respir Crit Care Med 2010;182:1377-1386.
85. Vanhorebeek I, Gunst J, Derde S, Derese I, Boussemaere M, Guiza F, Martinet W, Timmermans JP, D'Hoore A, Wouters PJ, et al. Insufficient activation of autophagy allows cellular damage to accumulate in critically ill patients. J Clin Endocrinol Metab 2011;96:E633-E645.
86. Rennie MJ. Anabolic resistance in critically ill patients. Crit Care Med 2009;37:S398-S399.
87. Gibson JN, Halliday D, Morrison WL, Stoward PJ, Hornsby GA, Watt PW, Murdoch G, Rennie MJ. Decrease in human quadriceps muscle protein turnover consequent upon leg immobilization. Clin Sci (Lond) 1987;72:503-509.
88. Vesali RF, Cibicek N, Jakobsson T, KlaudeM,Wernerman J, Rooyackers O. Protein metabolism in leg muscle following an endotoxin injection in healthy volunteers. Clin Sci (Lond) 2010;118:421-427.
89. Kumar V, Selby A, Rankin D, Patel R, Atherton P, Hildebrandt W, Williams J, Smith K, Seynnes O, Hiscock N, et al. Age-related differences in the dose-response relationship of muscle protein synthesis to resistance exercise in young and old men. J Physiol 2009; 587:211-217.
90. Biolo G, Fleming RY, Maggi SP, Nguyen TT, Herndon DN, Wolfe RR. Inverse regulation of protein turnover and amino acid transport in skeletal muscle of hypercatabolic patients. J Clin Endocrinol Metab 2002;87:3378-3384.
91. Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, Gonzalez M, Yancopoulos GD, Glass DJ. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004;14:395-403.
92. Plant PJ, Brooks D, Faughnan M, Bayley T, Bain J, Singer L, Correa J, Pearce D, Binnie M, Batt J. Cellular markers of muscle atrophy in chronic obstructive pulmonary disease (COPD). Am J Respir Cell Mol Biol 2010;42:461-471.
93. Doucet M, Russell AP, Leger B, Debigare R, Joanisse DR, Caron MA, LeBlanc P, Maltais F. Muscle atrophy and hypertrophy signaling in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:261-269.
94. Greenhaff PL, Karagounis LG, Peirce N, Simpson EJ, Hazell M, Layfield R, Wackerhage H, Smith K, Atherton P, Selby A, et al. Disassociation between the effects of amino acids and insulin on signaling, ubiquitin ligases, and protein turnover in human muscle. Am J Physiol Endocrinol Metab 2008;295:E595-E604.
95. Wilkinson SB, Phillips SM, Atherton PJ, Patel R, Yarasheski KE, Tarnopolsky MA, Rennie MJ. Differential effects of resistance and endurance exercise in the fed state on signalling molecule phosphorylation and protein synthesis in human muscle. J Physiol 2008; 586:3701-3717.
96. Reid MB, Moylan JS. Beyond atrophy: redox mechanisms of muscle dysfunction in chronic inflammatory disease. J Physiol 2011;589:2171-2179.
97. Coirault C, Guellich A, Barbry T, Samuel JL, Riou B, Lecarpentier Y. Oxidative stress of myosin contributes to skeletal muscle dysfunction in rats with chronic heart failure. Am J Physiol Heart Circ Physiol 2007;292:H1009- H1017.
98. Dalla LL, Ravara B, Gobbo V, Danieli BD, Germinario E, Angelini A, Vescovo G. Skeletal muscle myofibrillar protein oxidation in heart failure and the protective effect of carvedilol. J Mol Cell Cardiol 2005;38:803-807.
99. Yende S, Waterer GW, Tolley EA, Newman AB, Bauer DC, Taaffe DR, Jensen R, Crapo R, Rubin S, Nevitt M, et al. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. Thorax 2006;61:10-16.
100. Cicoira M, Bolger AP, Doehner W, Rauchhaus M, Davos C, Sharma R, Al-Nasser FO, Coats AJ, Anker SD. High tumour necrosis factor-a levels are associated with exercise intolerance and neurohormonal activation in chronic heart failure patients. Cytokine 2001;15:80-86.
101. Vescovo G, Ravara B, Dalla LL. Skeletal muscle myofibrillar protein oxidation and exercise capacity in heart failure. Basic Res Cardiol 2008;103:285-290.
102. Hardin BJ, Campbell KS, Smith JD, Arbogast S, Smith J, Moylan JS, Reid MB. TNF-a acts via TNFR1 and muscle-derived oxidants to depress myofibrillar force in murine skeletal muscle. J Appl Physiol 2008;104:694-699.
103. Weber-Carstens S, Deja M, Koch S, Spranger J, Bubser F, Wernecke KD, Spies CD, Spuler S, Keh D. Risk factors in critical illness myopathy during the early course of critical illness: a prospective observational study. Crit Care 2010;14:R119.
104. Brealey D, Karyampudi S, Jacques TS, Novelli M, Stidwill R, Taylor V, Smolenski RT, Singer M. Mitochondrial dysfunction in a long-term rodent model of sepsis and organ failure. Am J Physiol Regul Integr Comp Physiol 2004;286:R491-R497.
105. Rooyackers OE, Hesselink MK, Wagenmakers AJ. Contraction failure of skeletal muscle of rats recovering from critical illness. Clin Sci (Lond) 1997;92:189-195.
106. Rooyackers OE, Gijsen AP, Saris WH, Soeters PB, Wagenmakers AJ. Derangement in aerobic and anaerobic energy metabolism in skeletal muscle of critically ill and recovering rats. Biochim Biophys Acta 1996;1315:55-60.
107. Crouser ED, Julian MW, Blaho DV, Pfeiffer DR. Endotoxin-induced mitochondrial damage correlates with impaired respiratory activity. Crit Care Med 2002;30:276-284.
108. Vanhorebeek I, De VR, Mesotten D, Wouters PJ, De Wolf-Peeters C, Van den Berghe G. Protection of hepatocyte mitochondrial ultrastructure and function by strict blood glucose control with insulin in critically ill patients. Lancet 2005;365:53-59.
109. Brealey D, Brand M, Hargreaves I, Heales S, Land J, Smolenski R, Davies NA, Cooper CE, Singer M. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 2002;360: 219-223.
110. Carre JE, Orban JC, Re L, Felsmann K, Iffert W, Bauer M, Suliman HB, Piantadosi CA, Mayhew TM, Breen P, et al. Survival in critical illness is associated with early activation of mitochondrial biogenesis. Am J Respir Crit Care Med 2010;182:745-751.
111. Fredriksson K, Tjader I, Keller P, Petrovic N, Ahlman B, Scheele C, Wernerman J, Timmons JA, Rooyackers O. Dysregulation of mitochondrial dynamics and the muscle transcriptome in ICU patients suffering from sepsis induced multiple organ failure. PLoS One 2008; 3:e3686.
112. Vanhorebeek I, Gunst J, Derde S, Derese I, Boussemaere M, D'Hoore A, Wouters PJ, Van den Berghe G. Mitochondrial fusion, fission, and biogenesis in prolonged critically ill patients. J Clin Endocrinol Metab 2012;97:E59-E64.
113. Lehnart SE. Novel targets for treating heart and muscle disease: stabilizing ryanodine receptors and preventing intracellular calcium leak. Curr Opin Pharmacol 2007;7:225-232.
114. Bellinger AM, Mongillo M, Marks AR. Stressed out: the skeletal muscle ryanodine receptor as a target of stress. J Clin Invest 2008; 118:445-453.
115. Green HJ, BurnettM, Duhamel TA, D'Arsigny C, O'Donnell DE, Webb KA, Ouyang J. Abnormal sarcoplasmic reticulum Ca21-sequestering properties in skeletal muscle in chronic obstructive pulmonary disease. Am J Physiol Cell Physiol 2008;295:C350-C357.
116. Teener JW, Rich MM. Dysregulation of sodium channel gating in critical illness myopathy. J Muscle Res Cell Motil 2006;27:291-296.
117. Rossignol B, Gueret G, Pennec JP, Morel J, Giroux-Metges MA, Talarmin H, Arvieux CC. Effects of chronic sepsis on the voltagegated sodium channel in isolated rat muscle fibers. Crit Care Med 2007;35:351-357.
118. Rich MM, Teener JW, Raps EC, Schotland DL, Bird SJ. Muscle is electrically inexcitable in acute quadriplegic myopathy. Neurology 1996;46:731-736.
119. Lefaucheur JP, Nordine T, Rodriguez P, Brochard L. Origin of ICU acquired paresis determined by direct muscle stimulation. J Neurol Neurosurg Psychiatry 2006;77:500-506.
120. Weber-Carstens S, Koch S, Spuler S, Spies CD, Bubser F, Wernecke KD, Deja M. Nonexcitable muscle membrane predicts intensive care unit-acquired paresis in mechanically ventilated, sedated patients. Crit Care Med 2009;37:2632-2637.
121. Haeseler G, Foadi N, Wiegand E, Ahrens J, Krampfl K, Dengler R, Leuwer M. Endotoxin reduces availability of voltage-gated human skeletal muscle sodium channels at depolarized membrane potentials. Crit Care Med 2008;36:1239-1247.
122. Cesari M, Fielding RA, Pahor M, Goodpaster B, Hellerstein M, Van Kan GA, Anker SD, Rutkove S, Vrijbloed JW, Isaac M, et al. Biomarkers of sarcopenia in clinical trials: recommendations from the International Working Group on Sarcopenia. J Cachexia Sarcopenia Muscle 2012;3:181-190.
123. Sakuma K, Yamaguchi A. Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass. J Cachexia Sarcopenia Muscle 2012;3:77-94.
124. Narici MV, Maffulli N. Sarcopenia: characteristics, mechanisms and functional significance. Br Med Bull 2010;95:139-159.
125. Thornell LE. Sarcopenic obesity: satellite cells in the aging muscle. Curr Opin Clin Nutr Metab Care 2011;14:22-27.
126. Peterson CM, Johannsen DL, Ravussin E. Skeletal muscle mitochondria and aging: a review. J Aging Res 2012;2012:194821.
127. Jaquet JB, Luijsterburg AJ, Kalmijn S, Kuypers PD, Hofman A, Hovius SE. Median, ulnar, and combined median-ulnar nerve injuries: functional outcome and return to productivity. J Trauma 2001; 51:687-692.
128. Ruijs AC, Jaquet JB, Kalmijn S, Giele H, Hovius SE. Median and ulnar nerve injuries: a meta-analysis of predictors of motor and sensory recovery after modern microsurgical nerve repair. Plast Reconstr Surg 2005;116:484-494.
129. Bain JR, Hason Y, Veltri K, Fahnestock M, Quartly C. Clinical application of sensory protection of denervated muscle. J Neurosurg 2008;109:955-961.